Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: A meta-analysis

Institute for Molecular Cardiovascular Research and Interdisciplinary Center for Clinical Research BIOMAT, RWTH University Hospital Aachen, Aachen, Germany.
Journal of Cellular and Molecular Medicine (Impact Factor: 4.01). 07/2006; 10(3):727-33. DOI: 10.1111/j.1582-4934.2006.tb00432.x
Source: PubMed


Recent clinical studies have demonstrated that intracoronary infusion of autologous bone marrow cells (BMC) in conjunction with standard treatment may improve left ventricular function after an acute myocardial infarction (AMI). However, the results of these studies remain controversial, as the studies were relatively small in size and partially differed in design. We reviewed primary controlled randomized clinical studies comparing intracoronary transfer of autologous non-mobilized BMC combined with standard therapy versus standard therapy alone in patients with AMI. We identified five randomized controlled clinical trials, three of which were also placebo- and bone marrow aspiration-controlled. Non-mobilized BMC were infused into the revascularized coronary target artery 6.6 +/- 6.1 days after AMI. The mean follow- up period of 5.2 +/- 1.1 months was completed by 482 patients, 241 of which received infusion of BMC. The effect of BMC on left ventricular ejection fraction (LVEF) as a major functional parameter was evaluated. Analyzing the overall effect on the change in LVEF between baseline and follow-up value revealed a significant improvement in the BMCtreated group as compared to the control group (P = 0.04). Thus, considering the increase in LVEF during follow-up, transplantation of BMC may be a safe and beneficial procedure to support treatment of AMI. However, the functional improvement observed with this form of therapy was altogether relatively moderate and the studies were heterogeneous in design. Hence, further efforts aiming at large-scale, double-blind, randomized and placebo-controlled multi-center trials in conjunction with better definition of patients, which benefit from BMC infusion, appear to be warranted.

Full-text preview

Available from:
  • Source
    • "In theory, the injected exogenous MSCs may have a capacity to restore or stimulate the resident/endogenous stem cells' capacity to regenerate damaged heart tissue [5] [6] [7]. However, despite the initial enormous expectation, recent clinical trials have shown only moderate improvement of left ventricular function but no obvious evidence of therapeutic effectiveness [8] [9] [10] [11] [12]. Our preclinical animal research also demonstrated that direct injection of autologous MSCs promotes angiogenesis and improves left ventricular ejection faction following chronic myocardial ischemia, but no myocardiogenesis was observed [13] [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studying the proliferative ability of human bone marrow derived mesenchymal stem cells in hypoxic conditions can help us achieve the effective regeneration of ischemic injured myocardium. Cardiac-type fatty acid binding protein (FABP3) is a specific biomarker of muscle and heart tissue injury. This protein is purported to be involved in early myocardial development, adult myocardial tissue repair and responsible for the modulation of cell growth and proliferation. We have investigated the role of FABP3 in human bone marrow derived mesenchymal stem cells under ischemic conditions. MSCs from 12 donors were cultured either in standard normoxic or modified hypoxic conditions, and the differential expression of FABP3 was tested by quantitative (rt)PCR and western blot. We also established stable FABP3 expression in MSCs and searched for variation in cellular proliferation and differentiation bioprocesses affected by hypoxic conditions. We identified: 1) the FABP3 differential expression pattern in the MSCs under hypoxic conditions; 2) over-expression of FABP3 inhibited the growth and proliferation of the MSCs; however, improved their survival in low oxygen environments; 3) the cell growth factors and positive cell cycle regulation genes, such as PCNA, APC, CCNB1, CCNB2 and CDC6 were all down-regulated; while the key negative cell cycle regulation genes TP53, BRCA1, CASP3 and CDKN1A were significantly up-regulated in the cells with FABP3 overexpression. Our data suggested that FABP3 was up-regulated under hypoxia; also negatively regulated the cell metabolic process and the mitotic cell cycle. Overexpression of FABP3 inhibited cell growth and proliferation via negative regulation of the cell cycle and down-regulation of cell growth factors, but enhances cell survival in hypoxic or ischemic conditions.
    Full-text · Article · Feb 2014 · Experimental Cell Research
  • Source
    • "A brief description of several of these trials is shown in Table 2. As a whole, a recent systematic review (Abdel-Latif et al 2007) and a meta-analysis (Hristov et al 2006) conclude that these interventions are feasible, safe, and associated to a small increase in left ventricular ejection fraction (LVEF). In addition, a recent meta-regression using data from ten studies show a dose-response effect for the infused volume when the ejection fraction is measured (Lipinski et al 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerotic cardiovascular disease is the leading cause of death and a major part of its pathophysiology remains obscure. Some hematological targets have been related to the development and clinical outcome of this disease, especially soluble cytokines, leukocytes, red blood cells, hemostatic factors and platelets, and bone-marrow vascular progenitors. These emerging factors may be modulated by current antiatherosclerotic pharmacotherapy, target-designed novel drugs or progenitor cell therapy. The aim of current review article is to comprehensively review the role of these antiatherosclerotic targets and therapy.
    Preview · Article · Oct 2008 · Targets & therapy
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we specify the SET/A protocol which is an agent-based payment protocol for credit card transactions in UML statechart diagrams. Then we translate them into the NuSMV language and analyze the payment protocol using the NuSMV model checker. Although the payment protocol satisfies desired properties including data integrity and deadlock freedom in the absence of an agent failure, a failure analysis reveals that not all desired properties are satisfied when the agent crashes. The agent may fail while it is travelling to a merchant's server or when it is running in the merchant's server. To ensure that a transaction is resilient to the agent failure, an extended SET/A protocol is proposed. Whenever a timeout occurs, the cardholder sends an inquiry request to the merchant directly for finding out the transaction result. Our work contributes the e-commerce field by using an integrated approach for modelling and analyzing the SET/A protocol.
    No preview · Conference Paper · Aug 2004
Show more